Neuralstem, Inc. (NYSE MKT:CUR), a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous …
Neuralstem, Inc. (NYSEMKT:CUR) shares jumped over 8% in pre market trading to $2.
In a research report issued Monday, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on shares of Neuralstem, Inc. (NYSE MKT:CUR), with an $8.
Neuralstem, Inc. (NYSE MKT:CUR) a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous …
Maxim Group's healthcare analyst Jason Kolbert came out with a negative view on Neuralstem, Inc. (NYSE MKT:CUR), after the company reported its fourth-quarter results and provided …
Brean Capital’s healthcare analyst Jonathan Aschoff weighed in today with a few insights on Neuralstem, Inc. (NYSE MKT:CUR), after the company released its fourth-quarter results and …
Neuralstem, Inc. (NYSE MKT: CUR) reported its financial results for the fourth quarter and year ended December 31, 2014.
In a research note published Thursday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Neuralstem, Inc. (NYSE MKT:CUR) with an $8 price target, after …
Neuralstem, Inc. (NYSE MKT: CUR) announced top line data from the Phase II trial of NSI-566 spinal cord-derived neural stem cells under development for …
